idelalisib and Leukemia--Prolymphocytic--B-Cell
idelalisib has been researched along with Leukemia--Prolymphocytic--B-Cell* in 3 studies
Trials
1 trial(s) available for idelalisib and Leukemia--Prolymphocytic--B-Cell
Article | Year |
---|---|
Idelalisib-rituximab induces durable remissions in TP53 disrupted B-PLL but results in significant toxicity: updated results of the UK-wide compassionate use programme.
Topics: Aged; Female; Humans; Leukemia, Prolymphocytic, B-Cell; Male; Middle Aged; Mutation; Purines; Quinazolinones; Remission Induction; Rituximab; Tumor Suppressor Protein p53; United Kingdom | 2019 |
Other Studies
2 other study(ies) available for idelalisib and Leukemia--Prolymphocytic--B-Cell
Article | Year |
---|---|
Venetoclax is an option in B-cell prolymphocytic leukaemia following progression on B-cell receptor pathway inhibitors.
Topics: Adenine; Aged; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Drug Substitution; Humans; Leukemia, Prolymphocytic, B-Cell; Male; Piperidines; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Retreatment; Rituximab; Signal Transduction; Sulfonamides; Treatment Outcome | 2019 |
Idelalisib-Rituximab induces clinical remissions in patients with TP53 disrupted B cell prolymphocytic leukaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Genetic Variation; Humans; Leukemia, Prolymphocytic, B-Cell; Phenotype; Purines; Quinazolinones; Rituximab; Treatment Outcome; Tumor Suppressor Protein p53 | 2017 |